Rakuten Medical announces promising interim results from photoimmunotherapy study at ASCO 2024
Rakuten Medical, Inc., a pioneer in biotechnology focusing on precision, cell-targeting photoimmunotherapy, unveiled updated interim results from its Phase 1b/2 study of ASP-1929 photoimmunotherapy in combination with anti-PD-1 therapy. The data, presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) on June 2, 2024, provides new insights into the treatment of […]